Introduction
mTNBC
TRIPLE-NEGATIVE BREAST CANCER, DISEASES, METASTATIC BREAST CANCER, METASTATIC MELANOMA
Despite significant therapeutic advances in metastatic melanoma and metastatic triple-negative breast cancer (mTNBC), these diseases remain formidable contributors of cancer-related mortality and morbidity, warranting the exploration of novel approaches. For patients with metastatic melanoma, molecularly targeted therapies and immune checkpoint inhibitors have improved survival (The A prior study evaluated intratumoral administration of mRNA-transfected cMET CAR T cells in patients with metastatic breast cancer (